| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2848997 | American Heart Journal | 2009 | 8 Pages |
Abstract
Rosiglitazone appears not to lower LL or reduce angiographic progression of NCCL in DM2 and had complex effects on markers of cardiac risk.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Aloke V. MD, Jae S. BS, Michael BS, Maureen RN, Enrico MD, Raphael M. Byrne, Jeffrey BS, Johanna BS, Adnan MD, Albert MD, Olga BS, Igor MD, Michael C. MPH, Herman K. MD,